ALS Studies and Lessons Learned From COVID-19

 

The disruptions caused by COVID-19 have complicated both the initiation and execution of clinical trials involving therapies targeting amyotrophic lateral sclerosis (ALS). Read our experts’ perspectives on how to flex during this global pandemic.

VIEW PDF

Questions regarding your upcoming clinical trial?